抗新型冠狀病毒（SARS-CoV-2）口服藥物介紹

Oral Antiviral Treatments for COVID-19

截至2021年底已有兩種COVID-19口服抗病毒藥物問世，分別為Nirmatrelvir + Ritonavir (Paxlovid)及Molnupiravir (Lagevrio)，讓輕度至中度的確診患者有機會在家中就能獲得藥物治療。兩種口服藥物皆用於具任一重症風險因子，未使用氧氣且於發病五天內之COVID-19確診者；其中Paxlovid適用於12歲以上，而Lagevrio限用於18歲以上且臨床上不適用其他COVID-19治療選擇者。給藥時須注意兩者的服藥顆粒數不同，且因Paxlovid為CYP3A抑制劑，應特別小心藥物交互作用，並留意腎功能異常時需調整劑量。本文針對兩種抗新冠病毒口服藥物進行介紹與比較，並期待在不久的將來有更多對抗新冠病毒的藥物問世！

Two oral antiviral treatments for COVID-19 are available since 2021, including nirmatrelvir + ritonavir (Paxlovid) and molnupiravir (Lagevrio). Patients diagnosed with mild-tomoderate COVID-19 can be treated at home instead being hospitalized. When patient diagnosed with COVID-19 within five days, either Paxlovid or Lagevrio can be provided to whom without using oxygen, and at high risk for progression to severe COVID-19. Paxlovid is applicable for pediatric patients over 12 years of age, while Lagevrio is only available for adults who are not suitable for other treatments. It should be noticed that the number of tablets to take at once is different between the two. While Paxlovid contains a CYP3A inhibitor, drug-drug interactions should be considered. Furthermore, we should pay attention to patients' renal function for dosage adjustment when using Paxlovid. We introduced and made comparisons of the two oral treatments in this article and look forward to more antivirus treatments for COVID-19 in the future.